SCHEMBL15207896

SCHEMBL15207896

N#Cc1ccc(-c2nccn3nc(Nc4ccc(Cl)cc4)nc23)cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.40
CDK4 P11802 1/20 0.38
CCND3 P30281 1/20 0.38
AURKA O14965 1/20 0.37
JAK2 O60674 4/20 0.37
JAK3 P52333 4/20 0.37
PTK2 Q05397 4/20 0.37
SYK P43405 1/20 0.37
EIF2AK4 Q9P2K8 1/20 0.37
TUBB4A P04350 1/20 0.37
TUBB P07437 1/20 0.37
TUBA3C P0DPH7 1/20 0.37
TUBA1B P68363 1/20 0.37
TUBA4A P68366 1/20 0.37
TUBB4B P68371 1/20 0.37
TUBB3 Q13509 1/20 0.37
TUBB2A Q13885 1/20 0.37
TUBB8 Q3ZCM7 1/20 0.37
TUBA3E Q6PEY2 1/20 0.37
TUBA1A Q71U36 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15206787 0.88 JAK2 (0.48) AURKAJAK2JAK3PTK2ALDH1A1
SCHEMBL21220 0.87 CHEK1 (0.38) CHEK1JAK2JAK3PTK2SYK
SCHEMBL19607 0.86 SYK (0.40) CHEK1JAK2JAK3PTK2SYK
SCHEMBL19101 0.85 TRPA1 (0.44) CHEK1JAK2JAK3PTK2ABL1
SCHEMBL15207680 0.85 CHEK1 (0.36) CHEK1JAK2JAK3PTK2SYK
SCHEMBL31418 0.84 MAPT (0.41) SYKEIF2AK4MEN1LMNAKMT2A
SCHEMBL20159 0.84 SCN9A (0.42) AURKAJAK2JAK3PTK2SYK
SCHEMBL19843 0.84 SYK (0.40) AURKAJAK2JAK3PTK2SYK
SCHEMBL21617 0.82 SYK (0.38) CHEK1JAK2JAK3PTK2SYK
SCHEMBL15207711 0.82 PIK3CA (0.45) CDK4CCND3AURKAJAK2SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609098-B1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GMBH (DE) 2016-07-13 EP disclosed
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-9023851-B2 Triazolopyrazine derivatives MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225568-A1 TRIAZOLOPYRAZINE DERIVATIVES SYK, IRAK1, ZAP70 CHEK1 1302/4885CDK4 1132/4885CCND3 795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.